article thumbnail

J&J's patient assistance program suffers data breach, IBM says

Fierce Pharma

IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.

Patients 334
article thumbnail

J&J, IBM face class-action lawsuit over patient data breach

Fierce Pharma

As if the talc product liability lawsuits weren’t enough headache for Johnson & Johnson, the New Jersey pharma is now facing another lawsuit from patients, this time about a recent data breach. |

Patients 265
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

BioLineRx's Aphexda scores FDA nod to help myeloma patients undergo stem cell transplants

Fierce Pharma

After 10 years of stagnation, a new FDA approval could help more cancer patients become eligible for stem cell transplants. |

FDA 252
article thumbnail

Seagen, Genmab's Tivdak improves survival for cervical cancer patients in phase 3 trial

Fierce Pharma

As the Federal Trade Commission (FTC) scrutinizes Pfizer’s $43 billion Seagen buyout, the antibody-drug conjugate (ADC) specialist has notched a phase 3 win that could broaden its cervical cancer a | The drug boosted overall survival, progression-free survival and objective response rates in patients with recurrent or metastatic cervical cancer who (..)

Patients 261
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development? Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.

article thumbnail

Jazz Pharmaceuticals: 20 years of patient impact

Fierce Pharma

In this interview, Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, discusses Jazz’s 20-year legacy and what it means to create an organization that is both patient-focused and a great place | Jazz Pharmaceuticals’ Chairman and CEO discusses the company’s longstanding history of bringing new medicines to patients with limited or no options.

article thumbnail

FDA warns patients about compounded versions of Novo Nordisk's Ozempic, Wegovy

Fierce Pharma

FDA warns patients about compounded versions of Novo Nordisk's Ozempic, Wegovy kdunleavy Wed, 05/31/2023 - 13:02

FDA 341